Search

Gerstner Sloan Kettering held its inaugural retreat, on April 30 and May 1, to foster scientific and personal exchanges between students and faculty.

… Saturday, May 15, 2010 Gerstner Sloan Kettering held its inaugural retreat, on April 30 and May 1, to foster scientific and personal exchanges between students and faculty. The retreat brought together 32 students and 28 faculty members, as well as school leadership and keynote speakers for two days

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer progression and its ability to evolve resistance to treatment, MSK researchers have found in a laboratory study of lung cancer.

… Wednesday, January 21, 2026 A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer progression and its ability to evolve resistance to treatment. Targeting this subpopulation of “highly plastic” cells may make current treatments more

Learn about MSK research showing that bacteria inside head and neck tumors can make a difference in their response to immunotherapy.

… Friday, January 2, 2026 In cancer research, failure can lead to an important discovery. That’s what happened when an international multicenter trial led by  MSK radiation oncologist and early drug development specialist Nancy Lee, MD , tried combining radiation and chemotherapy with an immunotherapy

Tumors with a biomarker called high microsatellite instability have been linked to inherited cancer mutations.

… Saturday, June 2, 2018 Summary MSK researchers have found that tumors with a particular genetic marker are likely to be associated with Lynch syndrome. Memorial Sloan Kettering researchers have found that the genetic condition Lynch syndrome may be associated with more cancers than earlier thought. Lynch

MSK researchers developed an artificial intelligence system to detect cancer on digitized microscope slides.

… Monday, July 15, 2019 VIDEO | 00:45 Thomas Fuchs discusses how the computer model uses artificial intelligence to analyze digitized patient slides and detect cancer. Video Details Summary Cancer pathologists can spend hours each day studying slides that may yield little useful information. A type of

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Tuesday, March 16, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Chrysothemis Brown Receives a 2021 Parker Institute for Cancer Immunotherapy Award Chrysothemis Brown Chrysothemis (Chryssie) Brown, MBBS, PhD , was recently awarded a 2021 Parker Institute

Memorial Sloan Kettering (MSK) has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research. The award recognizes promising investigators aged 45 or younger for their efforts in advancing cancer research.

… Tuesday, September 29, 2015 Memorial Sloan Kettering (MSK) has named three investigators as recipients of this year’s  Paul Marks Prize for Cancer Research . The award recognizes promising investigators aged 45 or younger for their efforts in advancing cancer research. The winners are Bradley Bernstein

Two of the year's top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators.

… Monday, February 6, 2012 Summary Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators. Two of the top five advances in cancer research for 2011 cited by the annual progress report of the American Society

Clinicians and scientists at MSK continue to investigate new ways to improve outcomes for patients with thyroid cancer. Recent research insights from MSK thyroid cancer experts include, the safety and feasibility of active surveillance for certain patients, the identification of mutation profiles of subgroups, recommendations for future clinical trials of redifferentiation therapy, and study results showing that larotrectinib may be beneficial for treatment-naïve patients with NTRK fusion-positive thyroid cancer.

… Thursday, July 10, 2025 Clinicians and scientists at Memorial Sloan Kettering Cancer Center (MSK) continue to investigate new ways to improve outcomes for patients with thyroid cancer. Recent research insights from MSK thyroid cancer experts include: the safety and feasibility of active surveillance

Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering simultaneously presented today at the American Society of Clinical Oncology annual meeting and published online in the New England Journal of Medicine.

… Sunday, May 31, 2015 Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers